111 (YI) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
17 Jan, 2026Key challenges in China's pharmaceutical supply chain
Market fragmentation with thousands of companies and distributors limits scale and efficiency.
Lack of digitization and transparency creates friction and inefficiencies.
Limited supply chain optimization leads to excess stock and high stock-out rates.
Technology and operational solutions
Over 30 proprietary systems developed for supply chain management, including demand forecasting and price intelligence.
Innovations have reduced procurement costs from over 5% to 2.6% of revenue in five years.
Digital tools extend to partners, providing visibility and optimization for both upstream and downstream stakeholders.
Fulfillment network scale and models
Operates 13 fulfillment centers, including five super hubs in major cities, covering all of China.
Uses a mix of self-built, partner-transformed, and franchise models, all with standardized systems and quality control.
New fulfillment centers reduce setup time by 70% through partnerships.
Latest events from 111
- First-ever annual operating profit and positive cash flow achieved amid revenue decline.YI
Q4 202417 Mar 2026 - Operational profitability sustained, efficiency and digitalization drive growth amid flat revenue.YI
Q2 202423 Jan 2026 - Profitability, expansion, and digital innovation drive strong outlook amid favorable policy shifts.YI
Fireside Chat with Water Tower Research22 Jan 2026 - Operational profitability and improved margins achieved despite revenue decline and industry headwinds.YI
Q3 202412 Jan 2026 - Sustained profitability, digital innovation, and demographic trends drive optimism despite challenges.YI
Fireside Chat11 Jan 2026 - Asset-light transition delivers operational profitability and cash flow amid revenue decline.YI
Q3 202530 Dec 2025 - Operational profit, positive cash flow achieved; AI and network expansion to drive 2025 growth.YI
Status Update26 Dec 2025 - Operational profitability sustained amid revenue decline, with improved efficiency and cash flow.YI
Q2 202522 Sep 2025 - Stable revenues and operational profitability achieved amid challenging market conditions.YI
Q1 202522 Jun 2025